Is NCT06586957 recruiting in Fairway, KS?

Yes, NCT06586957 is currently recruiting participants at its Fairway, KS location. This solid tumor clinical trial is actively enrolling qualified participants.

How do I join the solid tumor clinical trial in Fairway?

To join this clinical trial in Fairway, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Fairway clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Solid Tumor Clinical Trial in Fairway, KS

About This Solid Tumor Study in Fairway

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).

Sponsor: NiKang Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

\- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only: subjects must be refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition. Dose Escalation:

Ovarian cancer

Endometrial cancer (only endometrioid subtype will require CCNE1 amplification)

Gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma with CCNE1 amplification

Small cell lung cancer (SCLC)

Triple-negative breast cancer (TNBC; HER2, estrogen receptor and progesterone receptor negative)

HR+ (includes estrogen-receptor or progesterone-receptor) and HER2- breast cancer (must have progressed following treatment with a CDK4/6 inhibitor, and is not suitable for endocrine therapy \[ET\])

Other solid tumors with CCNE1 amplification Dose Expansion: Part 2A: HR+ and HER2- breast cancer that is locally advanced and unresectable (Stage III) or metastatic (Stage IV); previously treated with ≥1 line of standard of care (SOC) including CDK4/6 inhibitor plus ET and not suitable for further ET. Subjects must have progressed after receiving therapy for ≥3 months in the metastatic setting or for ≥6 months in the adjuvant setting. Subjects must have received ≤2 lines of systemic cytotoxic therapy (chemotherapy or cytotoxic antibody drug conjugate \[ADC\]) in the metastatic setting.. Part 2B: Advanced platinum-based-chemotherapy resistant or refractory epithelial ovarian/fallopian/primary peritoneal carcinoma or clear cell ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least one platinum containing therapy and previously treated with ≤4 prior lines of systemic therapy administered for advanced/metastatic disease and with CCNE1 amplification. Part 2C: Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma with progression on at least one systemic therapy and previously treated with ≤3 prior lines of systemic therapy administered for advanced/metastatic disease, with CCNE1 amplification as determined by NGS by local liquid or tissue test. Part 2D: Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced/metastatic disease with CCNE1 amplification. Part 2E: Advanced/recurrent uterine carcinosarcoma previously treated with 1 prior platinum-based chemotherapy regimen and ≤3 prior lines of systemic therapy. Prior bevacizumab or PARP inhibitors are allowed and must be at least 3 weeks prior to the start of study drug.

Have adequate organ function

Subjects with female reproductive organs must be surgically sterile, post-menopausal, or must be willing to use highly effective method(s) of contraception

Ability to swallow oral medications.

Consent to provide archived tumor tissues and paired tumor biopsy at pretreatment

Exclusion Criteria

Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and/or radiotherapy, or chemotherapy.

History of another malignancy with exceptions

History of lymphohistiocytic or lymphoid hyperplasia; hemophagocytic lymphohistiocytosis.

Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade ≤ 1 severity (per CTCAE)

Clinically significant cardiovascular event within 6 months prior to start of NKT3964 treatment

Known active CNS metastases and/or carcinomatous meningitis

Active interstitial lung disease currently requiring treatment

History of uveitis, retinopathy or other clinically significant retinal disease

Active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease

Active wound healing from major surgery within 1 month or minor surgery within 10 days before the first dose of NKT3964.

Known human immunodeficiency virus (HIV), active hepatitis B or C infection

Prior investigative treatment with a selective or nonselective CDK2 inhibitor or degrader

Childs-Pugh class B or C cirrhosis or any other clinically significant liver disorder

Palliative radiation therapy within 14 days or other radiation therapy within 4 weeks prior to C1D1

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fairway?

Yes, this clinical trial (NCT06586957) has an active research site in Fairway, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Treatment Options in Fairway, KS

If you're searching for solid tumor treatment options in Fairway, KS, this clinical trial (NCT06586957) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fairway research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor clinical trials near you to find additional studies recruiting in your area.

Solid Tumor Clinical Trial in Fairway, KS

Expert Care in Fairway

IRB Approved

No-Cost Care

Apply for This Fairway Location

Why Participate?

Simple Process